ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABVC vs CPHI // FORWARD P/E MULTIPLE

ABVC BioPharma Inc. (NASDAQ) VS. China Pharma Holdings Inc. (NYSE) • 15-METRIC TALLY: ABVC 1 — CPHI 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABVC VS. CPHI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABVC CPHI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — -3.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -11.40% -23.60 CPHI /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.76% 0.32% -11.08 CPHI /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -8.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 4/9 -3.00 CPHI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.3 40.2 +8.08 ABVC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $27.8M $28.0M -$202.0K CPHI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABVC REV CPHI REV ABVC GROSS % CPHI GROSS % ABVC FCF CPHI FCF
FY 2025 $0 $4.1M — -3.2% -$3.0M $88.9K
FY 2024 $509.6K $4.5M 98.0% -43.8% -$1.8M -$444.5K
FY 2023 $152.4K $7.0M — — -$4.2M -$699.7K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABVC // BETA —
CPHI // BETA —